An analysis of tumor necrosis for α gene polymorphisms and haplotypes with natural clearance of hapatitis C virus infection

Genes and Immunity

Volumn 5, Issue 4, 2004, Pages 294-300

  Thio, C L ^a   Goedert, J J ^b   Mosbruger, T ^a   Vlahov, D ^c   Strathdee, S A ^d   O'Brien, S J ^e   Astemborski, J ^a   Thomas, D L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Laboratory of Genomic Diversity   (United States)

Author keywords

Genetic epidemiology; Genetics; Infectious diseases; TNF; Viral hepatitis

Indexed keywords

CYTOSINE; GUANINE; HLA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNOLOGY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOPATHOGENESIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NEGRO; NONHUMAN; OUTCOMES RESEARCH; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; WILD TYPE;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

HEPATITIS C VIRUS;

EID: 3242682495     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364072     Document Type: Article

References (42)

1. Anonymous. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S-10S.
2. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914.
3. Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
4. Rehermann B, Chang KM, McHutchison J et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70: 7092-7102.
5. Thio CL, Thomas DL, Goedert JJ et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16-21.
6. Thio CL, Gao X, Goedert JJ et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792-4797.
7. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-2124.
8. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-452.
9. Koziel MJ, Dudley D, Afdhal N et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus - identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 2311-2321.
10. Nelson DR, Lim HL, Marousis CG et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-2494.
11. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994; 179: 841-848.
12. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-217.
13. Lio D, Caruso C, Di Stefano R et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64: 674-680.
14. Constantini PK, Wawrzynowicz-Syczewska R, Clare M et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-412.
15. Hohler T, Kruger A, Gerken G et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-177.
16. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-390.
17. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-277.
18. Schiemann U, Glas J, Torok P et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003; 68: 1-4.
19. Negoro K, Kinouchi Y, Hiwatashi N et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117: 1062-1068.
20. Seki N, Yamaguchi K, Yamada A et al. Polymorphism of the 5′-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. J Infect Dis 1999; 180: 880-883.
21. Barrett S, Collins M, Kenny C et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212-218.
22. Rosen HR, McHutchison JG, Conrad AJ et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714-720.
23. Yee LJ, Tang J, Gibson AW et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-712.
24. Skoog T, van't Hooft FM, Kallin B et al. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet 1999; 8: 1443-1449.
25. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-612.
26. Uglialoro AM, Turbay D, Pesavento PA et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52: 359-367.
27. Hohjoh H, Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun 2001; 2: 105-109.
28. Udalova IA, Richardson A, Denys A et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000; 20: 9113-9119.
29. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
30. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-406.
31. Danis VA, Millington M, Hyland V et al. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995; 12: 127-133.
32. Huizinga TW, Westendorp RG, Bollen EL et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
33. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
34. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46: 32-41.
35. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
36. Villano SA, Vlahov D, Nelson KE et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 3274-3277.
37. Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995; 74: 212-220.
38. Vlahov D, Anthony JC, Munoz A et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109: 75-100.
39. Goedert JJ, Kessler CM, Aledort LM et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-1148.
40. Hilgartner MW, Donfield SM, Willoughby A et al. Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol 1993; 15: 208-218.
41. Richardson A, Sisay-Joof F, Ackerman H et al. Nucleotide diversity of the TNF gene region in an African village. Genes Immun 2001; 2: 343-348.
42. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.